Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 4Adenocarcinoma 2Pancreatic Ductal Adenocarcinoma 1Neoplasms 1Carcinoma, Pancreatic Ductal 1

Interventions

titanium silicide 1mitazalimab 1irinotecan sucrosofate 1devimistat 1S 1 (combination) 1PEGPH20 1Oxaliplatin 1Irinotecan 1Gemcitabine 1Escitalopram 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Pancreatic Ductal Adenocarcinoma × PEGPH20 × Clear all
NCT04134468 2020-01-31

MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma

Abramson Cancer Center at Penn Medicine

Phase 2 Withdrawn
Gastrointestinal

Pancreatic Ductal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡